(Q36447526)

14 August 2017

1 reference

title

The risk of breast, endometrial and ovarian cancer in users of hormonal preparations (English)

1 reference

14 August 2017

1 reference

Leslie Bernstein

1

1 reference

PubMed ID

16611204

14 August 2017

language of work or name

1 reference

1 March 2006

1 reference

Basic and Clinical Pharmacology and Toxicology

14 August 2017

1 reference

14 August 2017

98

1 reference

14 August 2017

3

1 reference

14 August 2017

288-296

1 reference

Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial

14 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

"Incessant ovulation" and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

The Power of the Pill: Oral Contraceptives and Women’s Career and Marriage Decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

The epidemiology of endometrial cancer in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Oral contraceptives and the risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Breast cancer and hormone-replacement therapy in the Million Women Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Endometrial cancer and hormone-replacement therapy in the Million Women Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Prevention of cancers of the breast, endometrium and ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Oral contraceptives and breast cancer in young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Risk Factors for Invasive Epithelial Ovarian Cancer: Results from a Swedish Case-Control Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_277.X

10.1111/J.1742-7843.2006.PTO_277.X

21 January 2018

Identifiers

DOI

1 reference

release_cxo3vdepjzfepcdn4ylpdhgaqy

14 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cxo3vdepjzfepcdn4ylpdhgaqy

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16611204

1 reference

PubMed ID

16611204